Nicholas Opie, the co-founder of Synchron and a leading figure in Australian neurotechnology, has joined the board of ASX-listed assistive-technology company Control Bionics as Non-Executive Director and strategic advisor. The appointment was announced this week and is intended to strengthen Control Bionics’ technical, clinical and commercialisation capabilities across assistive communication, rehabilitation, sports performance, and the wider neurotechnology market. As part of the engagement, Control Bionics’ board has resolved to seek shareholder approval at the company’s 2026 annual general meeting to issue Opie 1.25 million options vesting in equal tranches over four years and expiring in May 2031.
Opie’s existing footprint in Australian neurotechnology
Opie co-founded Synchron, the endovascular brain-computer interface company building the Stentrode device. Synchron was founded in Melbourne and is now headquartered in New York after its commercial centre of gravity shifted to the United States. He also co-founded Ultra Bionics, which is developing minimally invasive ultrasonic deep-brain neuromodulation. His academic anchor is the University of Melbourne, where he heads the Vascular Bionics Laboratory. With the Control Bionics appointment, Opie’s neurotechnology footprint now spans four institutional positions.
What Control Bionics adds to the picture
Control Bionics is an Australian assistive-communication and rehabilitation technology company, ASX-listed under the ticker CBL and headquartered in Cremorne. Its core product is NeuroNode, available in Trilogy, Duo, and Eye-gaze Duo configurations, enabling people with speech and movement difficulties to control computers and connected devices. The product line operates downstream of the clinical brain-computer interface category that Synchron addresses, in the assistive-tech market that paralysed and movement-impaired users actually adopt at scale. The category includes communication aids, rehabilitation devices, and integrated control interfaces for daily living. Opie’s appointment positions him at both ends of the commercial bridge that clinical-stage BCI eventually needs to cross. Synchron is moving toward US regulatory approval and pivotal trial enrolment. Control Bionics operates in the market that will be the natural commercial destination for the patient population those BCI trials are targeting.
The Australian neurotechnology ecosystem hardens
Australia’s National Reconstruction Fund Corporation invested AUD 54 million in Synchron in November 2025, channelling federal sovereign capital into the country’s largest BCI export. The Synchron founding team and intellectual property originated in Melbourne. The Vascular Bionics Laboratory at the University of Melbourne is the academic anchor for that work and for Ultra Bionics. Control Bionics is the assistive-technology commercial node. Opie now sits at four points across this ecosystem simultaneously, which gives Australian neurotechnology a degree of internal coordination unusual in a category where founders typically scatter across the United States after raising venture capital.
What to watch
Shareholder approval for the Opie options package at Control Bionics’ 2026 annual general meeting is the next procedural milestone. The four-year vesting structure expiring in May 2031 sets a commitment horizon that signals Opie expects to remain materially involved with Control Bionics through the next regulatory and commercial cycle for the broader BCI category. Practical signals to watch over the next twelve months include any technical or clinical collaboration disclosures between Control Bionics and Synchron, any integration work between Control Bionics’ assistive-communication platform and emerging non-invasive or minimally invasive BCI signals, and any further board or advisory moves by Opie across the Australian neurotechnology cohort.
Sources: Neurotechnology leader Nicholas Opie joins Control Bionics board (Biotech Dispatch Australia, May 2026). Professor Nicholas Opie, University of Melbourne expert profile. Synchron founding history and Australian origin coverage (InnovationAus). NRFC AUD 54 million investment in Synchron (National Reconstruction Fund Corporation).